Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Advancements in Diagnosis, Treatment for Antiphospholipid Syndrome

Lara C. Pullen, PhD  |  July 14, 2017

CHICAGO—Doruk Erkan, MD, MPH, a rheumatologist at the Hospital for Special Surgery and Weill Cornell Medicine in New York City, described recent developments in the field of antiphospholipid syndrome (APS) to the rheumatologists gathered for the ACR’s State-of-the-Art Clinical Symposium in April. He introduced APS as a “field with limited data and lots of controversies,” although,…

Amyloidosis Is Often Underdiagnosed, Undertreated

Lara C. Pullen, PhD  |  July 14, 2017

CHICAGO—Caryn A. Libbey, MD, clinical associate professor of medicine at Boston University School of Medicine, described the evolving in our understanding of amyloid at the ACR’s State-of-the-Art Clinical Symposium in April. Amyloidosis is a rare disease that is often underdiagnosed and undertreated. “Even though this disease has been around for 150 years, I still consider it…

Rheumatologist Dr. Santosh Bhusal Shares Insights in Move from Fellowship to Practice

Santosh Bhusal, MD, with Terence W. Starz, MD, on behalf of the ARHP Practice Committee  |  July 14, 2017

“I was hoping for good news, but now I am worried,” was the response of a 29-year-old patient when I suggested an oncology referral. He was four months into treatment of dermatomyositis and had experienced significant improvement of his muscle strength, CPK levels and interstitial pneumonitis, but a follow-up CT scan showed that his spleen…

ARHP Member Karla Jones Builds Network within Pediatric Rheumatology

Erin Latimer Meadows  |  July 14, 2017

Questions that come to mind when you are specialized within a subspecialty: How can I build a network of peers? Where can I find resources and tools that apply to me? Do organizations exist that can provide me with opportunities for growth and leadership? As a pediatric nurse practitioner in rheumatology at Nationwide Children’s Hospital…

racorn/shutterstock.com

EULAR Releases 2016 Recommendations on RA Management

Mary Beth Nierengarten  |  July 14, 2017

Management of rheumatoid arthritis (RA) is complex. The ever-expanding availability of new drugs requires that rheumatologists and patients constantly consider treatment strategies and targets aimed at both disease control and symptom relief while remaining cognizant of the increasing high cost of emerging medications. Given such complexity, guidelines to inform rheumatologists about the most recent developments…

Essential Collaboration: Rheumatologists & PTs Must Work Together

Richard Quinn  |  July 14, 2017

The importance of rheumatologists and physical therapists (PTs) working together for patients cannot be understated. Carol Oatis, PT, PhD, says, “Rheumatologists and PTs have very similar goals. … Collaboration is essential for optimal outcomes.”…

Juvenile-Onset Arthritis Bodes Worse Pregnancy Outcomes

David Douglas  |  July 13, 2017

NEW YORK (Reuters Health)—Women with a diagnosis of juvenile idiopathic arthritis (JIA) are at increased risk of pregnancy complications, according to Swedish researchers. As Dr. Katarina Remaeus told Reuters Health by email, “In our cohort study . . . we found an association with adverse pregnancy outcomes including preterm birth, induction of labor and delivery…

Predictive Value of Whole-Body MRI & Ultrasound Explored in EULAR Studies

Thomas R. Collins  |  July 13, 2017

Highlights from the 2017 EULAR Congress MADRID—Researchers say that whole-body MRI could yield an earlier diagnosis of spondyloarthropathy (SpA) in patients with early inflammatory joint symptoms, according to findings presented in a poster session at the Annual European Congress of Rheumatology (EULAR). The approach could lead to earlier treatment and better outcomes, they say. Investigators…

RA Treatments Show Mixed Results

Thomas R. Collins  |  July 13, 2017

Highlights from the 2017 EULAR Congress MADRID—The anti-IL6 “nanobody,” vobarilizumab, produced mixed results when used with methotrexate (MTX), compared with MTX and placebo, according to results of a 24-week, double-blind Phase 2b study of patients with rheumatoid arthritis (RA), which were presented in an abstract session at the Annual European Congress of Rheumatology (EULAR). The…

Tofacitinib with Methotrexate Not Inferior to Adalimumab with Methotrexate

Thomas R. Collins  |  July 13, 2017

Highlights from the 2017 EULAR Congress MADRID—Tofacitinib (a JAK inhibitor) used with methotrexate (MTX) is not inferior to adalimumab (a TNF inhibitor) plus MTX in rheumatoid arthritis (RA) patients who’ve had an inadequate response to MTX alone, according to results of a Phase 3B/4 trial presented in a session at the Annual European Congress of…

  • « Previous Page
  • 1
  • …
  • 414
  • 415
  • 416
  • 417
  • 418
  • …
  • 816
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences